DRTSW
Alpha Tau Medical Ltd.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 11 ▲ Alpha Tau presented interim data from its REGAIN trial of Alpha DaRT…
- Jun 1 ▲ Alpha Tau announced positive overall survival results from pooled Ph…
- Jun 3 ▲ Alpha Tau Medical Ltd. announced a strategic collaboration with Tolm…
- Jun 3 Contract: Alpha Tau and Tolmar Announce Strategic Collaboration to B…
- Aug 14 ▲ Short interest falls 70.3% to 3.1K
- Aug 31 ▼ Short interest jumps 72.3% to 5.3K
- Sep 30 ▼ Short interest jumps 121.2% to 8.9K
- Oct 15 ▲ Short interest falls 31.4% to 6.1K
- Oct 19 FDA: Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S…
- Oct 22 Contract: Alpha Tau and Samsung Medical Center Sign MOU to Explore C…
- Oct 29 Activist stake: Alpha Tau Announces Inclusion in the Flagship TA-90 and TA…
- Nov 15 FDA: Alpha Tau Announces New Positive Interim Results from its…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2026: 1 added (0 new), 2 trimmed or exited.
- Short sellersSTEADY
Short interest +0.8% to 6.1K shares. 1.0 days to cover, ≈0.0% of shares.
- TrendDOWNTREND
15% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value | |
|---|---|---|---|
| UBS Group AG | NEAR_EXIT | $1.4K | |
| LMR Partners LLP | DOUBLED | $4.4M | |
| WOLVERINE ASSET MANAGEMENT LLC | DOUBLED | $943.7K | |
| 🔒 Fresh data, subscribers only | ADD | ||
| 🔒 Fresh data, subscribers only | TRIM | ||
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $166.7K |
| Next Q | None | None | No data | $333.3K |
| Current FY | None | None | No data | $503.3K |
| Next FY | None | None | No data | $10.7M |
Short side
FINRA· Oct 30, 2026SecBot reports
14 filings · 9 bullish · 0 bearish · 5 neutral- BULLISH 6-KJun 3, 2026
Alpha Tau Medical Ltd. announced a strategic collaboration with Tolmar International Ltd. to…
The collaboration provides near-term capital and validates Alpha DaRT's commercial potential, but the stock is likely to react positively to the premium equity investment and partnership with a…
- BULLISH 6-KJun 1, 2026
Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic…
The strong survival and safety data is a significant catalyst for DRTSW. Expect short-term volatility as the market digests the ASCO presentation. Monitor upcoming IMPACT and ACAPELLA trial updates…
- NEUTRAL 6-KMay 18, 2026
Alpha Tau reported Q1 2026 financial results with net loss widening to $22.9M ($0.26/share) from…
The clinical catalysts (REGAIN data, ReSTART enrollment completion, PMDA approval) are positive but pre-revenue biotech with widening losses and non-cash warrant volatility. Key binary events…
- BULLISH 6-KMay 11, 2026
Alpha Tau presented interim data from its REGAIN trial of Alpha DaRT for recurrent glioblastoma…
The strong early efficacy data is a positive catalyst, but the small sample and need for FDA review to complete enrollment warrant caution. Monitor for completion of the 10-patient pilot and any…
All DRTSW filing & press-release reports (14)
- 6-K reportJun 3, 2026
- 6-K reportJun 1, 2026
- 6-K reportMay 18, 2026
- 6-K reportMay 11, 2026
- 6-K reportMay 11, 2026
- 6-K reportMay 8, 2026
- 6-K reportMay 8, 2026
- 6-K reportMay 7, 2026
- 6-K reportMay 5, 2026
- 6-K reportMay 4, 2026
- EFFECT reportMay 4, 2026
- 6-K reportApr 27, 2026
- 6-K reportApr 23, 2026
- 6-K reportMar 31, 2026